FR2824478B1 - Nouvelle utilisation du ncs-1(neuron specific calcium sensor-1)pour le traitement des troubles du snc et le developpement d'agents therapeutiques - Google Patents

Nouvelle utilisation du ncs-1(neuron specific calcium sensor-1)pour le traitement des troubles du snc et le developpement d'agents therapeutiques

Info

Publication number
FR2824478B1
FR2824478B1 FR0204797A FR0204797A FR2824478B1 FR 2824478 B1 FR2824478 B1 FR 2824478B1 FR 0204797 A FR0204797 A FR 0204797A FR 0204797 A FR0204797 A FR 0204797A FR 2824478 B1 FR2824478 B1 FR 2824478B1
Authority
FR
France
Prior art keywords
ncs
development
treatment
therapeutic agents
cns disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0204797A
Other languages
English (en)
Other versions
FR2824478A1 (fr
Inventor
Patrick Nef
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01109536A external-priority patent/EP1250931A1/fr
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of FR2824478A1 publication Critical patent/FR2824478A1/fr
Application granted granted Critical
Publication of FR2824478B1 publication Critical patent/FR2824478B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR0204797A 2001-04-17 2002-04-17 Nouvelle utilisation du ncs-1(neuron specific calcium sensor-1)pour le traitement des troubles du snc et le developpement d'agents therapeutiques Expired - Fee Related FR2824478B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01109536A EP1250931A1 (fr) 2001-04-17 2001-04-17 Nouvelle utilisation du neuronal calcium sensor-1 (ncs-1) pour le traitement de troubles du système nerveux central et pour le développement d'agents thérapeutiques
EP01125816 2001-10-29

Publications (2)

Publication Number Publication Date
FR2824478A1 FR2824478A1 (fr) 2002-11-15
FR2824478B1 true FR2824478B1 (fr) 2007-09-21

Family

ID=26076547

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0204797A Expired - Fee Related FR2824478B1 (fr) 2001-04-17 2002-04-17 Nouvelle utilisation du ncs-1(neuron specific calcium sensor-1)pour le traitement des troubles du snc et le developpement d'agents therapeutiques

Country Status (6)

Country Link
US (1) US7230155B2 (fr)
JP (1) JP2003040801A (fr)
CH (1) CH697372B1 (fr)
DE (1) DE10217066A1 (fr)
FR (1) FR2824478B1 (fr)
GB (2) GB2377635B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006043710A1 (fr) * 2004-10-19 2006-04-27 Reverse Proteomics Research Institute Co., Ltd. Protéine cible et gène cible pour le développement de médicaments et procédé de recherche par criblage
US20110214195A1 (en) * 2008-11-10 2011-09-01 The Regents Of The University Of Colorado, A Body Corporate Methods For Treating Clinical Conditions Associated With Lipoprotein Lipase Activity
EP3432911A1 (fr) * 2016-03-23 2019-01-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Ciblage du capteur de calcium neuronal 1 pour le traitement du syndrome de wolfram
CN107736311B (zh) * 2017-11-21 2023-04-11 湖南卢氏环保科技有限公司 黑水虻养殖系统及控制方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH31213A (en) * 1993-05-25 1998-05-05 Daiichi Seiyaku Co Drug for neuroprotection.
US5624902A (en) * 1995-06-07 1997-04-29 Torrey Pines Institute For Molecular Studies Peptide inhibitors of calmodulin
US5981279A (en) * 1995-11-09 1999-11-09 Allegheny University Of The Health Sciences Compositions and methods to regulate calmodulin gene expression, and uses thereof for influencing cell growth and differentiation
EP0948632A1 (fr) 1996-10-31 1999-10-13 Smithkline Beecham Corporation Procedes de caracterisation et de selection de motifs cibles d'arn liant des composes pharmaceutiques
US6165709A (en) * 1997-02-28 2000-12-26 Fred Hutchinson Cancer Research Center Methods for drug target screening
AU4080199A (en) 1998-05-22 1999-12-13 Incyte Pharmaceuticals, Inc. Calmodulin related protein
WO1999061008A2 (fr) 1998-05-26 1999-12-02 Peter Louis Carlen Compositions et procedes servant a soulager les fonctions mentales deficientes ou la perte de memoire et a limiter la duree de recuperation chez le mammifere anesthesie
CN1287171A (zh) * 1999-09-07 2001-03-14 复旦大学 人神经元钙传感蛋白及其编码序列、以及制法和用途
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation

Also Published As

Publication number Publication date
JP2003040801A (ja) 2003-02-13
FR2824478A1 (fr) 2002-11-15
GB0507998D0 (en) 2005-05-25
GB2377635A (en) 2003-01-22
CH697372B1 (de) 2008-09-15
US7230155B2 (en) 2007-06-12
GB2377635B (en) 2005-10-19
US20030159158A1 (en) 2003-08-21
GB2411403A (en) 2005-08-31
GB0208525D0 (en) 2002-05-22
DE10217066A1 (de) 2002-10-31

Similar Documents

Publication Publication Date Title
FR2785521B1 (fr) Dispositif de suspension pour le traitement de prolapsus et d'incontinences urinaires
FR2697162B1 (fr) Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
DZ1716A1 (fr) Méthode et mécanisme pour l'enlevement et le traitement des déchets.
FR2732357B1 (fr) Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
MA27027A1 (fr) Inhibiteur de pde4 et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
FR2742331B1 (fr) Instrument pour l'execution d'une therapie endoscopique
DZ3027A1 (fr) Composés et procédés pour le traitement de l'asthme, de l'allergie et des troubles inflammatoires.
MA26950A1 (fr) Nouveaux retinoides pour le traitement de l'emphyseme
FR2705966B1 (fr) Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
FR2741262B1 (fr) Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
FR2824478B1 (fr) Nouvelle utilisation du ncs-1(neuron specific calcium sensor-1)pour le traitement des troubles du snc et le developpement d'agents therapeutiques
FR2792835B3 (fr) Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
FR2764811B3 (fr) Appareil pour le traitement physique des yeux
FR2717080B1 (fr) Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
FR2808202B1 (fr) Modification de la concentration ionique d'un fluide cervical pour le traitement de troubles neurologiques
FR2808894B1 (fr) Procede et appareil photographique a usage unique pour empecher la reutilisation non-autorisee de l'appareil
FR2824742B1 (fr) Dispositif de reeducation des vertiges et des troubles de l'equilibre
FR2716623B1 (fr) Utilisation d'un dérivé tricyclique pour l'obtention de médicaments destinés au traitement des troubles mnémo-cognitifs.
FR2756183B1 (fr) Association d'huile et de peptides d'argan utile pour le traitement des troubles lies au vieillissement cutane
FR2803764B1 (fr) Dispositif de reeducation a plateau tournant pour le traitement des vertiges et des troubles de l'equilibre
FR2792199B3 (fr) Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
MA26908A1 (fr) S-methyl-dihydro-ziprasidone pour le traitement de troubles psychiatriques et oculaires
DZ3320A1 (fr) Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20091231